The Board of Bactiguard Holding AB (publ.) announced that Christine Lind will assume the role as CEO per 12 April 2024 which is just over a month earlier than previously communicated. Thomas von Koch, Board Member and interim CEO hand over the CEO role to Christine. Christine Lind has broad experience, both strategic and operational, from more than 25 years in the healthcare sector.

Born in 1974 in the US and living in Sweden since 2015, she holds a BSc in Finance & Information Systems from New York University and an MBA from Columbia Business School. During her career, she has held CEO and executive level positions in business development and strategy at biotech companies, including BioArctic AB, Medivir AB and LifeCell Corporation. Christine also spent 10 years as an investment banker at Merrill Lynch in New York, where she advised biotech and pharmaceutical companies on licensing, M&A and financing.

She most recently served as Senior Vice President Corporate Development at SSI Strategy/NDA Group AB.